Search Results - "Kolenc Peitl, P"
-
1
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
Published in EJNMMI radiopharmacy and chemistry (29-06-2017)“…Background Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as…”
Get full text
Journal Article -
2
Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals
Published in EJNMMI radiopharmacy and chemistry (21-03-2016)“…This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of…”
Get full text
Journal Article -
3
PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In
Published in Molecular pharmaceutics (03-11-2014)“…Cholecystokinin-2 (CCK-2) receptors, overexpressed in cancer types such as small cell lung cancers (SCLC) and medullary thyroid carcinomas (MTC), may serve as…”
Get full text
Journal Article -
4
On-cartridge preparation and evaluation of 68Ga-, 89Zr- and 64Cu-precursors for cell radiolabelling
Published in Nuclear medicine and biology (01-04-2019)“…Indium-111 when formulated as indium-111 oxine remains the gold standard for long term cell tracking, whereas radiometals for improved PET applications still…”
Get full text
Journal Article -
5
On-cartridge preparation and evaluation of 68 Ga-, 89 Zr- and 64 Cu-precursors for cell radiolabelling
Published in Nuclear medicine and biology (01-04-2019)“…Indium-111 when formulated as indium-111 oxine remains the gold standard for long term cell tracking, whereas radiometals for improved PET applications still…”
Get full text
Journal Article -
6
-
7
PET and SPECT Imaging of a Radiolabeled Minigastrin Analogue Conjugated with DOTA, NOTA, and NODAGA and Labeled with 64Cu, 68Ga, and 111In
Published in Molecular pharmaceutics (03-11-2014)“…Cholecystokinin-2 (CCK-2) receptors, overexpressed in cancer types such as small cell lung cancers (SCLC) and medullary thyroid carcinomas (MTC), may serve as…”
Get full text
Journal Article